Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg
MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) — OTC Markets Group (OTCQX: OTCM), operator of
EarthDaily Satellite Deploys MAPLE GROVE, Minn., May 04, 2026 (GLOBE NEWSWIRE) — EarthDaily Analytics (EarthDaily)
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) — OTC Markets Group (OTCQX: OTCM), operator of
Transaction with AEQUITA advances company’s portfolio realignment ROTTERDAM, Netherlands, May 01, 2026 (GLOBE NEWSWIRE) —
Transaction with AEQUITA advances company’s portfolio realignment ROTTERDAM, Netherlands, May 01, 2026 (GLOBE NEWSWIRE) —
Copyright © 2026 Cambodia News Service. All rights reserved.